South Korea
· Delayed Price · Currency is KRW Seoul Pharma Statistics
Total Valuation
Seoul Pharma has a market cap or net worth of KRW 44.66 billion.
| Market Cap | 44.66B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Seoul Pharma has 11.66 million shares outstanding.
| Shares Outstanding | 11.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +6.40% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 4.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 1.35.
| Current Ratio | 1.24 |
| Quick Ratio | 0.90 |
| Debt / Equity | 1.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.69 |
| Interest Coverage | 1.85 |
Financial Efficiency
Return on equity (ROE) is 5.12% and return on invested capital (ROIC) is 2.38%.
| Return on Equity (ROE) | 5.12% |
| Return on Assets (ROA) | 1.99% |
| Return on Capital (ROIC) | 2.38% |
| Revenue Per Employee | 245.79M |
| Profits Per Employee | 6.12M |
| Employee Count | 172 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 4.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +7.92% |
| 50-Day Moving Average | 4,085.60 |
| 200-Day Moving Average | 3,655.38 |
| Relative Strength Index (RSI) | 44.49 |
| Average Volume (20 Days) | 46,007 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Seoul Pharma had revenue of KRW 42.28 billion and earned 1.05 billion in profits.
| Revenue | 42.28B |
| Gross Profit | 21.70B |
| Operating Income | 1.58B |
| Pretax Income | 831.57M |
| Net Income | 1.05B |
| EBITDA | n/a |
| EBIT | 1.58B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 3.19 billion in cash and 28.39 billion in debt, giving a net cash position of -25.21 billion or -2,162.00 per share.
| Cash & Cash Equivalents | 3.19B |
| Total Debt | 28.39B |
| Net Cash | -25.21B |
| Net Cash Per Share | -2,162.00 |
| Equity (Book Value) | 21.04B |
| Book Value Per Share | 3,339.71 |
| Working Capital | 3.86B |
Cash Flow
In the last 12 months, operating cash flow was 3.35 billion and capital expenditures -13.90 billion, giving a free cash flow of -10.55 billion.
| Operating Cash Flow | 3.35B |
| Capital Expenditures | -13.90B |
| Free Cash Flow | -10.55B |
| FCF Per Share | -904.93 |
Margins
Gross margin is 51.33%, with operating and profit margins of 3.75% and 2.49%.
| Gross Margin | 51.33% |
| Operating Margin | 3.75% |
| Pretax Margin | 1.97% |
| Profit Margin | 2.49% |
| EBITDA Margin | n/a |
| EBIT Margin | 3.75% |
| FCF Margin | -24.96% |
Dividends & Yields
Seoul Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 35.60% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -23.63% |
Stock Splits
The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.
| Last Split Date | Apr 12, 2004 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Seoul Pharma has an Altman Z-Score of 1.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.68 |
| Piotroski F-Score | n/a |